Connect
Welcome to the online home of the Chris M. Carlos and Catherine Nicole Jockisch Carlos Endowment for Primary Sclerosing Cholangitis (PSC). Thanks to support provided by this endowment, dedicated Mayo Clinic investigators and their teams are making strides to better understand and treat PSC patients, with the ultimate goal of developing a cure for this disease.
Follow the PSC page and stay up-to-date as we post news about advances in PSC research, clinical trials, and available resources.
Public blog
Newsfeed
Primary Sclerosing Cholangitis (PSC) is a slowly progressing liver disease that lacks an ideal biomarker, which could predict disease progression. A biomarker is a measurable…
The American Association for the Study of Liver Disease (AASLD) is the leading society of scientists and health care professionals in the United States committed…
Clinical trials are an important aspect of our work as we try to find a medical therapy for patients suffering from Primary Sclerosing Cholangitis…
On June 28, 2019 the Extramural Advisory Committee (EAC) of the Carlos Research Program in PSC met in Rochester, Minnesota for our annual scientific retreat.…
The majority of patients with the PSC have Inflammatory Bowel Disease (IBD). The association of those two diseases is known for decades, yet the…
Female patients with the PSC and inflammatory bowel disease (IBD) have unique health and disease issues to deal with. During the 15th Annual Conference of…
On May 21-23, 2019, the 15th Annual Conference of the “PSC Partners Seeking a Cure” took place in Rochester, Minnesota. More than 315 patients and…
In a study published this month in Gut, T. Liwinski, et al., reports on the differences of the microbiome and bile acid composition seen in…
Recently, we have made the decision to include periodically in our PSC blog commentaries of selected clinical studies published by other groups. This tactic aims…
In this month’s issue of the Scandinavian Journal of Gastroenterology John E. Eaton et al., reports on the results of a 12-week open-label pilot study…
In a review published in Nature Reviews Gastroenterology and Hepatology this month (see below), Jesus Banales et al., provides an excellent and comprehensive overview…
Cell free DNA (cfDNA) are degraded DNA fragments released to the blood stream during health and disease. This discovery was made more than 50 years ago. However, it was…
In an abstract presented this week at the 2019 European Association for the Study of the Liver (EASL) meeting in Vienna, Austria, Dr. John Eaton…
We are privileged to host in Rochester, Minnesota the 15th annual conference for PSC patients and their caregivers (June 20-23, 2019). In a partnership with the PSC Partners Seeking…
In the early 1980s, Ravi Iyer, Ph.D., helped usher in a new application of artificial intelligence, one marked by the ability to predict when individual…
This Thursday, February 28th, we celebrate: "Rare Disease Day". Therefore, we dedicate this week's post to the anniversary of Rare Disease Day in an effort…
A decade ago, Tom Hemming Karlsen, M.D., Ph.D., who leads the Norwegian PSC Research Center (NoPSC), joined forces with Konstantinos Lazaridis, M.D., of Mayo Clinic…
For the past 15 years, PSC Partners Seeking a Cure has sought to be a safe haven, providing information and support, for those diagnosed…
Mayo Clinic is at the forefront of research designed to uncover the environment’s role in PSC, thanks to a unique collaboration with Gary Miller, PhD,…
This past year, our PSC team accomplished several important milestones that make us proud: We received an NIDDK award to study the pathogenesis and outcomes…
Connect